Q1 EPS Forecast for Clearside Biomedical Boosted by Analyst

Clearside Biomedical, Inc. (NASDAQ:CLSD - Free Report) - Investment analysts at HC Wainwright increased their Q1 2025 earnings per share (EPS) estimates for Clearside Biomedical in a research note issued on Monday, March 31st. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.12) per share for the quarter, up from their prior forecast of ($0.13). HC Wainwright currently has a "Buy" rating and a $6.00 target price on the stock. The consensus estimate for Clearside Biomedical's current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Clearside Biomedical's Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.45) EPS.

Other research analysts also recently issued research reports about the company. Chardan Capital reissued a "buy" rating and issued a $6.00 price target on shares of Clearside Biomedical in a research note on Friday, March 28th. StockNews.com cut Clearside Biomedical from a "hold" rating to a "sell" rating in a report on Tuesday, March 18th. Finally, Needham & Company LLC restated a "buy" rating and set a $4.00 target price on shares of Clearside Biomedical in a research report on Tuesday. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. According to MarketBeat, Clearside Biomedical has a consensus rating of "Moderate Buy" and a consensus price target of $5.25.

Clearside Biomedical Stock Up 0.7 %

NASDAQ CLSD traded up $0.01 during trading hours on Thursday, hitting $0.85. The company's stock had a trading volume of 65,550 shares, compared to its average volume of 349,585. The stock has a fifty day moving average of $0.96 and a 200 day moving average of $1.03. Clearside Biomedical has a twelve month low of $0.77 and a twelve month high of $1.65. The firm has a market capitalization of $65.65 million, a P/E ratio of -1.89 and a beta of 2.04.

Clearside Biomedical (NASDAQ:CLSD - Get Free Report) last released its earnings results on Thursday, March 27th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03. The business had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.27 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CLSD. Investor s Fiduciary Advisor Network LLC acquired a new stake in shares of Clearside Biomedical during the fourth quarter worth about $32,000. Northern Trust Corp raised its holdings in Clearside Biomedical by 24.0% during the 4th quarter. Northern Trust Corp now owns 165,499 shares of the company's stock worth $157,000 after buying an additional 32,048 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Clearside Biomedical by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 764,058 shares of the company's stock valued at $726,000 after buying an additional 32,672 shares in the last quarter. 18.75% of the stock is currently owned by institutional investors.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.